We only have this paper's title and publication details.
Read it at the sourceSurvival analysis demonstrates predictive power of complementary biomarkers in high-risk melanoma, indicating adjuvant immunotherapy benefits.
Supplementary Figure S2. Survival analysis flowchart.
No takes yet. Share an insight, caveat, or question.
Tarhini et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: